Focus on MPNs: Q&A with Dr. Aaron Gerds

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.

Dr. Aarong Gerds is a hemotologist oncologist at the Cleveland Clinic Taussig Cancer Institute where they subspecialize in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as myelodsyplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with a special emphasis on allogeneic hematopoietic cell transplantation. Dr. Gerds is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving on the Test Materials Development Committee. As Assistant Professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute, Dr. Gerds serves as the principal investigator for a number of clinical trials for the treatment of MPNs, and is focused on developing novel therapies for these patients